Deep Track Capital LP Grows Stake in enGene Holdings Inc. (NASDAQ:ENGN)

Deep Track Capital LP increased its holdings in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 74.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,557,575 shares of the company's stock after purchasing an additional 1,949,942 shares during the period. Deep Track Capital LP owned approximately 10.31% of enGene worth $30,308,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ENGN. Franklin Resources Inc. boosted its position in enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock valued at $7,854,000 after buying an additional 389,918 shares during the period. Blue Owl Capital Holdings LP grew its position in enGene by 3.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock worth $21,014,000 after acquiring an additional 101,006 shares during the last quarter. Corton Capital Inc. purchased a new position in enGene in the 4th quarter worth approximately $157,000. Jane Street Group LLC bought a new stake in enGene in the fourth quarter valued at approximately $93,000. Finally, Vontobel Holding Ltd. purchased a new stake in shares of enGene during the fourth quarter valued at approximately $69,000. Institutional investors own 64.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. HC Wainwright reiterated a "buy" rating and set a $25.00 price target on shares of enGene in a report on Tuesday, March 11th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price objective on shares of enGene in a research report on Tuesday, April 29th. Morgan Stanley lowered their target price on shares of enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. Piper Sandler assumed coverage on shares of enGene in a research report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price objective on the stock. Finally, UBS Group downgraded enGene from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $34.00 to $7.00 in a report on Friday, February 14th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $23.29.

enGene Stock Performance

NASDAQ ENGN traded down $0.43 on Friday, hitting $2.96. 32,954 shares of the company traded hands, compared to its average volume of 127,488. The business's 50 day moving average price is $4.40 and its 200-day moving average price is $6.28. enGene Holdings Inc. has a 52-week low of $2.94 and a 52-week high of $14.37. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $150.89 million, a price-to-earnings ratio of -5.10 and a beta of -0.36.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.